CUTIA-B Reports Annual Results: Shareholder Loss Narrows by 21.58% to RMB 340 Million

Stock News

Mar 24

CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to owners of the parent amounted to RMB 340 million, narrowing by 21.58% compared to the previous year. Loss per share was RMB 1.03.

The group's two main products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), began commercialization in late October 2025. For the year ended December 31, 2025, combined revenue from these two products exceeded RMB 100 million.

The group continued to optimize operational efficiency. During the year ended December 31, 2025, sales and distribution, research and development, and administrative expenses decreased by approximately RMB 109 million compared to the same period last year. The annual loss was reduced by about RMB 94 million year-on-year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1168828574"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168828574\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168828574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168828574","market":"sh","top_or_hot":-1,"title":"CUTIA-B Reports Annual Results: Shareholder Loss Narrows by 21.58% to RMB 340 Million","media":"Stock News","content":"<p>CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to owners of the parent amounted to RMB 340 million, narrowing by 21.58% compared to the previous year. Loss per share was RMB 1.03.</p>\n<p>The group's two main products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), began commercialization in late October 2025. For the year ended December 31, 2025, combined revenue from these two products exceeded RMB 100 million.</p>\n<p>The group continued to optimize operational efficiency. During the year ended December 31, 2025, sales and distribution, research and development, and administrative expenses decreased by approximately RMB 109 million compared to the same period last year. The annual loss was reduced by about RMB 94 million year-on-year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CUTIA-B Reports Annual Results: Shareholder Loss Narrows by 21.58% to RMB 340 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCUTIA-B Reports Annual Results: Shareholder Loss Narrows by 21.58% to RMB 340 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-24 16:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to owners of the parent amounted to RMB 340 million, narrowing by 21.58% compared to the previous year. Loss per share was RMB 1.03.</p>\n<p>The group's two main products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), began commercialization in late October 2025. For the year ended December 31, 2025, combined revenue from these two products exceeded RMB 100 million.</p>\n<p>The group continued to optimize operational efficiency. During the year ended December 31, 2025, sales and distribution, research and development, and administrative expenses decreased by approximately RMB 109 million compared to the same period last year. The annual loss was reduced by about RMB 94 million year-on-year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02487","symbol_name":"科笛-B","start_time":0,"source_url":"","article_id":"1168828574","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168828574","pubTimestamp":1774341515,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02487":"科笛-B","BK1161":"生物科技"},"translate_title":"CUTIA-B公布全年业绩：股东亏损收窄21.58%至人民币3.4亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":1},"content_text":"CUTIA-B (02487) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 336 million, an increase of 20.22% year-on-year. The loss attributable to owners of the parent amounted to RMB 340 million, narrowing by 21.58% compared to the previous year. Loss per share was RMB 1.03.\nThe group's two main products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), began commercialization in late October 2025. For the year ended December 31, 2025, combined revenue from these two products exceeded RMB 100 million.\nThe group continued to optimize operational efficiency. During the year ended December 31, 2025, sales and distribution, research and development, and administrative expenses decreased by approximately RMB 109 million compared to the same period last year. The annual loss was reduced by about RMB 94 million year-on-year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}